心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2019 专家共识：应用正性肌力药治疗急性和晚期心力衰竭

2019-09-06 国外心血管相关专家小组（统称） Int J Cardiol. 2019 Sep 6.

正性肌力药急性心力衰竭晚期心力衰竭

正性肌力药物是通过增加心肌收缩力增加心输出量，成为治疗失代偿心力衰竭的三大支柱药物之一。本文是由来自21个国家的专家在小组会议上提出的正性肌力药治疗急性和晚期心力衰竭共识。

中文标题：

2019 专家共识：应用正性肌力药治疗急性和晚期心力衰竭

英文标题：

A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus

发布机构：

国外心血管相关专家小组（统称）

发布日期：

2019-09-06

简要介绍：

正性肌力药物是通过增加心肌收缩力增加心输出量，成为治疗失代偿心力衰竭的三大支柱药物之一。本文是由来自21个国家的专家在小组会议上提出的正性肌力药治疗急性和晚期心力衰竭共识。

 

拓展指南：与心力衰竭相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2019 专家共识：应用正性肌力药治疗急性和晚期心力衰竭)] GetToolGuiderByIdResponse(projectId=1, id=139ff1c00180e6bd, title=2019 专家共识：应用正性肌力药治疗急性和晚期心力衰竭, enTitle=A pragmatic approach to the use of inotropes for the management of acute and advanced heart failure: An expert panel consensus, guiderFrom=Int J Cardiol. 2019 Sep 6., authorId=null, author=, summary=正性肌力药物是通过增加心肌收缩力增加心输出量，成为治疗失代偿心力衰竭的三大支柱药物之一。本文是由来自21个国家的专家在小组会议上提出的正性肌力药治疗急性和晚期心力衰竭共识。 , cover=, journalId=null, articlesId=null, associationId=738, associationName=国外心血管相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Fri Sep 06 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<P>正性肌力药物是通过增加心肌收缩力增加心输出量，成为治疗失代偿心力衰竭的三大支柱药物之一。本文是由来自21个国家的专家在小组会议上提出的正性肌力药治疗急性和晚期心力衰竭共识。 </P> <P> </P>拓展指南：<strong>与<font color=red>心力衰竭</font>相关指南：</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=bb8951c001800ac7" title="2019 ACC专家共识决策路径：心力衰竭住院患者的风险评估，管理和临床路径" target=_blank>2019 ACC专家共识决策路径：心力衰竭住院患者的风险评估，管理和临床路径</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=da43f1c001e717ad" title="中国成人心力衰竭超声心动图规范化检查专家共识" target=_blank>中国成人心力衰竭超声心动图规范化检查专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=0e4f91c001e71a83" title="2019 HFA/ESC专家共识：心力衰竭的药物治疗、程序、设备以及患者管理（更新版）" target=_blank>2019 HFA/ESC专家共识：心力衰竭的药物治疗、程序、设备以及患者管理（更新版）</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=02ae61c001e7102e" title="中国成人心力衰竭超声心动图规范化检查专家共识" target=_blank>中国成人心力衰竭超声心动图规范化检查专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=9b22a1c001e7062f" title="2019 HFA/ESC专家共识：心力衰竭的药物治疗、程序、设备以及患者管理（更新版）" target=_blank>2019 HFA/ESC专家共识：心力衰竭的药物治疗、程序、设备以及患者管理（更新版）</a></li> 更多信息请点击：<a href="https://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E5%8A%9B%E8%A1%B0%E7%AB%AD" target=_blank>有关心力衰竭更多指南</a></ul>, tagList=[TagDto(tagId=14301, tagName=正性肌力药), TagDto(tagId=7834, tagName=急性心力衰竭), TagDto(tagId=75805, tagName=晚期心力衰竭)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7314, appHits=641, showAppHits=18, pcHits=3582, showPcHits=4904, likes=62, shares=17, comments=7, approvalStatus=1, publishedTime=Tue Oct 22 21:59:35 CST 2019, publishedTimeString=2019-09-06, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Oct 22 21:59:35 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:32:57 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 专家共识：应用正性肌力药治疗急性和晚期心力衰竭)])
2019 专家共识：应用正性肌力药治疗急性和晚期心力衰竭
下载请点击：
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1057169, encodeId=520d105e169b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:33 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057166, encodeId=098c105e1660c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:12 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999704, encodeId=8091999e041b, content=哇，这个很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19265203583, createdName=147447a4m19暂无昵称, createdTime=Thu Jul 15 11:20:37 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891051, encodeId=debd891051fd, content=想要好好研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201010/0fafdb2489b9446a938ed330d4b9704c/edf844abfa224e66b2143c0d3cd0234f.jpg, createdBy=615c2242303, createdName=121484abm97(暂无昵称), createdTime=Sat Oct 10 13:36:04 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880593, encodeId=53ff880593d1, content=积分不够，怎么办, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62dc2474642, createdName=124459ffm51暂无昵称, createdTime=Sat Aug 29 14:27:46 CST 2020, time=2020-08-29, status=1, ipAttribution=)]
    2021-10-03 H8888888

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1057169, encodeId=520d105e169b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:33 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057166, encodeId=098c105e1660c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:12 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999704, encodeId=8091999e041b, content=哇，这个很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19265203583, createdName=147447a4m19暂无昵称, createdTime=Thu Jul 15 11:20:37 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891051, encodeId=debd891051fd, content=想要好好研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201010/0fafdb2489b9446a938ed330d4b9704c/edf844abfa224e66b2143c0d3cd0234f.jpg, createdBy=615c2242303, createdName=121484abm97(暂无昵称), createdTime=Sat Oct 10 13:36:04 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880593, encodeId=53ff880593d1, content=积分不够，怎么办, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62dc2474642, createdName=124459ffm51暂无昵称, createdTime=Sat Aug 29 14:27:46 CST 2020, time=2020-08-29, status=1, ipAttribution=)]
    2021-10-03 H8888888

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1057169, encodeId=520d105e169b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:33 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057166, encodeId=098c105e1660c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:12 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999704, encodeId=8091999e041b, content=哇，这个很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19265203583, createdName=147447a4m19暂无昵称, createdTime=Thu Jul 15 11:20:37 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891051, encodeId=debd891051fd, content=想要好好研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201010/0fafdb2489b9446a938ed330d4b9704c/edf844abfa224e66b2143c0d3cd0234f.jpg, createdBy=615c2242303, createdName=121484abm97(暂无昵称), createdTime=Sat Oct 10 13:36:04 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880593, encodeId=53ff880593d1, content=积分不够，怎么办, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62dc2474642, createdName=124459ffm51暂无昵称, createdTime=Sat Aug 29 14:27:46 CST 2020, time=2020-08-29, status=1, ipAttribution=)]
    2021-07-15 147447a4m19暂无昵称

    哇，这个很好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1057169, encodeId=520d105e169b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:33 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057166, encodeId=098c105e1660c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:12 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999704, encodeId=8091999e041b, content=哇，这个很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19265203583, createdName=147447a4m19暂无昵称, createdTime=Thu Jul 15 11:20:37 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891051, encodeId=debd891051fd, content=想要好好研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201010/0fafdb2489b9446a938ed330d4b9704c/edf844abfa224e66b2143c0d3cd0234f.jpg, createdBy=615c2242303, createdName=121484abm97(暂无昵称), createdTime=Sat Oct 10 13:36:04 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880593, encodeId=53ff880593d1, content=积分不够，怎么办, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62dc2474642, createdName=124459ffm51暂无昵称, createdTime=Sat Aug 29 14:27:46 CST 2020, time=2020-08-29, status=1, ipAttribution=)]
    2020-10-10 121484abm97(暂无昵称)

    想要好好研究

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1057169, encodeId=520d105e169b8, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=134, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:33 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1057166, encodeId=098c105e1660c, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=989a5607928, createdName=H8888888, createdTime=Sun Oct 03 16:32:12 CST 2021, time=2021-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999704, encodeId=8091999e041b, content=哇，这个很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=127, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19265203583, createdName=147447a4m19暂无昵称, createdTime=Thu Jul 15 11:20:37 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=891051, encodeId=debd891051fd, content=想要好好研究, beContent=null, objectType=guider, channel=null, level=null, likeNumber=191, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201010/0fafdb2489b9446a938ed330d4b9704c/edf844abfa224e66b2143c0d3cd0234f.jpg, createdBy=615c2242303, createdName=121484abm97(暂无昵称), createdTime=Sat Oct 10 13:36:04 CST 2020, time=2020-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880593, encodeId=53ff880593d1, content=积分不够，怎么办, beContent=null, objectType=guider, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62dc2474642, createdName=124459ffm51暂无昵称, createdTime=Sat Aug 29 14:27:46 CST 2020, time=2020-08-29, status=1, ipAttribution=)]
    2020-08-29 124459ffm51暂无昵称

    积分不够，怎么办

    0